Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study

18F-DOPA positron emission tomography (PET) has been used for two decades to study the organization and pathology of the striatal dopamine system in the human brain, particularly in Parkinson's disease. High resolution 3D PET allows a more detailed analysis than previously available and was employed in this study to determine the regional uptake of 18F-DOPA in control brain. Eleven healthy volunteers underwent 18F-DOPA PET with a region of interest (ROI) study performed using individual volumetric MRI's coregistered to the PET ADD image. A Patlak linear graphical analysis was undertaken to obtain influx constant (Ki) values. The highest Ki values were from neostriatal areas, with a rostrocaudal gradient of increasing Ki values from head of caudate nucleus to rostral putamen to caudal putamen. However, Ki values for transaxial slices from dorsal to ventral through the caudate and putamen were uniform. Ventral striatum Ki was 81% with red nucleus and globus pallidus Ki values of approximately 40% of neostriatum. In limbic areas, highest values were obtained from amygdala (35% neostriatal Ki). Neocortical Ki values varied from 22% in temporal pole to 6% in occipital cortex of neostriatal values. Hypothalamic Ki was high (45%) in comparison to thalamus (17%) and retina (17%). 18F-DOPA is taken up by serotonin (raphe, 51%), and noradrenaline (locus coeruleus, 37%) as well as dopamine neurons. These data indicate that 18F-DOPA PET can be used with detailed, anatomically based ROIs as a tool for in vivo analysis of regional changes in monoamine neuron systems throughout the brain in Parkinson's disease and other disorders.

[1]  J S Rakshi,et al.  Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET , 1998, Journal of neurology, neurosurgery, and psychiatry.

[2]  D J Brooks,et al.  An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. , 1996, Brain : a journal of neurology.

[3]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  D J Brooks,et al.  Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. , 1996, Brain : a journal of neurology.

[5]  D. Marshak Synaptic inputs to dopaminergic neurons in mammalian retinas. , 2001, Progress in brain research.

[6]  K. Jellinger,et al.  Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. , 1991, Molecular and chemical neuropathology.

[7]  D. Doudet,et al.  6-18F-DOPA PET study in patients with schizophrenia , 2000, Psychiatry Research: Neuroimaging.

[8]  C D Marsden,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[9]  P. Thompson,et al.  Isolated tremor and disruption of the nigrostriatal dopaminergic system , 1992, Neurology.

[10]  P Cumming,et al.  Controversies arising from recent FDOPA articles. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  G. Paxinos,et al.  THE HUMAN NERVOUS SYSTEM , 1975 .

[12]  T. Spinks,et al.  Physical characteristics of the ECAT EXACT3D positron tomograph. , 2000, Physics in medicine and biology.

[13]  C. Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  H. Braak,et al.  Nigral and extranigral pathology in Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.

[15]  K. Ohtsubo,et al.  Pineal gland in old age; quantitative and qualitative morphological study of 168 human autopsy cases , 1987, Brain Research.

[16]  Y. Agid,et al.  Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease , 1983, Brain Research.

[17]  K. Jellinger Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? , 1999, Journal of neural transmission. Supplementum.

[18]  H. Steinbusch,et al.  Distribution of serotonin-immunoreactivity in the central nervous system of the rat—Cell bodies and terminals , 1981, Neuroscience.

[19]  B. Berger,et al.  Alterations of dopaminergic and noradrenergic innervations in motor cortex in parkinson's disease , 1991, Annals of neurology.

[20]  D L Hill,et al.  Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. , 1997, Medical physics.

[21]  D. J. Brooks,et al.  Morphological and functional imaging studies on the diagnosis and progression of Parkinson’s disease , 2000, Journal of Neurology.

[22]  A. Parent,et al.  Dopaminergic innervation of human basal ganglia , 2000, Journal of Chemical Neuroanatomy.

[23]  C. Crouzel,et al.  Presynaptic dopaminergic function in the striatum of schizophrenic patients , 1997, Schizophrenia Research.

[24]  F. Fornai,et al.  The role of the locus coeruleus in the development of Parkinson's disease , 2000, Neuroscience & Biobehavioral Reviews.

[25]  B. Scatton,et al.  Parkinson's disease and dementia , 1987, Neurology.

[26]  David J Brooks,et al.  Plasticity of the nigropallidal pathway in Parkinson's disease , 2003, Annals of neurology.

[27]  T. Ishikawa,et al.  Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  V. Chan‐Palay,et al.  Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression , 1989, The Journal of comparative neurology.

[29]  W D Heiss,et al.  Increased pineal Fdopa uptake is related to severity of Parkinson's disease – A PET study , 2001, Journal of pineal research.

[30]  M Schulzer,et al.  Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism , 1994, Annals of neurology.

[31]  Alan C. Evans,et al.  Dopa decarboxylase activity of the living human brain. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Nahmias,et al.  Dopamine visualized in the basal ganglia of living man , 1983, Nature.

[33]  Andrew D. Roberts,et al.  FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa , 1999, Neurology.

[34]  C. Matthews,et al.  The pineal gland as an APUD organ: supporting evidence and implications. , 1979, Medical hypotheses.

[35]  Alan C. Evans,et al.  Human Striatal l-DOPA Decarboxylase Activity Estimated in vivo Using 6-[18F]fluoro-DOPA and Positron Emission Tomography: Error Analysis and Application to Normal Subjects , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  Takeo Ishigaki,et al.  Extrastriatal Mean Regional Uptake of Fluorine-18-FDOPA in the Normal Aged Brain—An Approach Using MRI-Aided Spatial Normalization , 2000, NeuroImage.